Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Regulatory Express: 100,000 Get Emergency Use COVID-19 Vaccines

Plus RWE For Pediatric Drug Guidelines

Executive Summary

Over 100,000 people in China have already been inoculated with Sinopharm's COVID-19 vaccine under an EUA. Meanwhile, the country's regulatory agency has conducted an internal audit of the vaccines oversight process, and is drawing up guidance on the use of real world evidence for pediatric drugs.

You may also be interested in...



Gene Editing In China: EdiGene Raises Fresh Funds, Aims For First IND

With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.

China Regulatory Express: New Cell Therapy, Gene Editing Guidelines Proposed

Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research. 

China Nears COVID Vaccine Race 'Victory': CNBG

China is nearing the finish line in the coronavirus vaccines race with just “the last kilometer to go”, and its government is already negotiating with the WHO for potential global supplies.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel